These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28345206)

  • 41. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
    Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
    Fernández-Rodríguez CM; Alonso S; Martinez SM; Forns X; Sanchez-Tapias JM; Rincón D; Rodriguez-Caravaca G; Bárcena R; Serra MA; Romero-Gómez M; Fernandez I; Garcia-Samaniego J; Fuente J; Solá R; Moreno-Otero R; Planas R;
    Am J Gastroenterol; 2010 Oct; 105(10):2164-72; quiz 2173. PubMed ID: 20700116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
    Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
    Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixco C; Decaestecker J; de Galocsy C; Janssens F; Van Overbeke L; Van Steenkiste C; D'Heygere F; Cool M; Wuyckens K; Nevens F; Robaeys G
    J Viral Hepat; 2017 Nov; 24(11):976-981. PubMed ID: 28504854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis.
    Villani R; Monami M; Di Cosimo F; Fioravanti G; Mannucci E; Vendemiale G; Serviddio G
    J Viral Hepat; 2019 Nov; 26(11):1249-1256. PubMed ID: 31243849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication.
    Kang Q; Chen J; Luo H; Tan N; Gao H; Zhang X; Yu M; Liu D; Xi H; An Y; Han Y; Cheng R; Xu X
    Dis Markers; 2020; 2020():8539804. PubMed ID: 33082884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    Elsherif O; Bannan C; Keating S; McKiernan S; Bergin C; Norris S
    PLoS One; 2017; 12(6):e0178398. PubMed ID: 28636638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C virus infection: Are there still specific problems with genotype 3?
    Gondeau C; Pageaux GP; Larrey D
    World J Gastroenterol; 2015 Nov; 21(42):12101-13. PubMed ID: 26576095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function.
    Davis JS; Young M; Lennox S; Jones T; Piera K; Pickles R; Oakley S
    Antivir Ther; 2018; 23(8):687-694. PubMed ID: 30048244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Application of direct antiviral drugs in special patients with HCV infection].
    Jiang C; Liu CY; Shao S; Gao YH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):316-320. PubMed ID: 29996347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antiviral treatment for hepatitis C among injecting drug users in the era of direct-acting antiviral agents].
    Pan L; Pang L
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):893-896. PubMed ID: 33105938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy.
    Mazzaro C; Dal Maso L; Visentini M; Ermacora A; Andreone P; Gattei V; Pozzato G
    Hematol Oncol; 2021 Oct; 39(4):439-447. PubMed ID: 34477233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
    Leblebicioglu H; Arends JE; Ozaras R; Corti G; Santos L; Boesecke C; Ustianowski A; Duberg AS; Ruta S; Salkic NN; Husa P; Lazarevic I; Pineda JA; Pshenichnaya NY; Tsertswadze T; Matičič M; Puca E; Abuova G; Gervain J; Bayramli R; Ahmeti S; Koulentaki M; Kilani B; Vince A; Negro F; Sunbul M; Salmon D;
    Antiviral Res; 2018 Feb; 150():9-14. PubMed ID: 29217468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS.
    Silva GF; Andrade VG; Moreira A
    Arq Gastroenterol; 2018; 55(4):343-345. PubMed ID: 30785516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.
    Di Minno MND; Ambrosino P; Buonomo AR; Pinchera B; Calcaterra I; Crispo M; Scotto R; Borgia F; Mattia C; Gentile I
    Intern Emerg Med; 2020 Mar; 15(2):263-271. PubMed ID: 31396919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.